Loading...
•
Apr 01, 2023
Hologic Q2 2023 Earnings Report
Revenue and earnings exceeded prior guidance, with strong growth across all core franchises.
Key Takeaways
Hologic reported a decrease in revenue by 28.5% to $1,026.5 million, primarily due to lower COVID-19 assay sales. Excluding COVID-19 revenues, total organic revenue grew by 20.2%. The company's GAAP diluted EPS was $0.87, and non-GAAP diluted EPS was $1.06, both exceeding guidance. Hologic raised its fiscal year 2023 revenue and EPS guidance.
Revenue decreased by 28.5% to $1,026.5 million, but exceeded prior guidance.
Excluding COVID-19 revenues, total organic revenue grew by 20.2%.
GAAP diluted EPS was $0.87, and non-GAAP diluted EPS was $1.06, both exceeding guidance.
The company raised its fiscal year 2023 revenue and EPS guidance.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Hologic raised its full-year guidance for both revenue and EPS, highlighting confidence in the remainder of the fiscal year despite an uncertain macro environment.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...